CrossLaps? for Culture (CTX-I) ELISA 品牌Immunoassay Systems | IDS

點(diǎn)擊看大圖

如果您對(duì)該產(chǎn)品感興趣的話,可以

產(chǎn)品名稱: CrossLaps? for Culture (CTX-I) ELISA 品牌Immunoassay Systems | IDS

產(chǎn)品型號(hào): AC-07F1

產(chǎn)品展商: 其他品牌

產(chǎn)品文檔: 無(wú)相關(guān)文檔

簡(jiǎn)單介紹

品名：CrossLaps? for Culture (CTX-I) ELISA 貨號(hào)：AC-07F1Code: AC-07F1 Certification: Research Use Only Clinical Area: Animal Research Type: Manual Format: ELISA RUO/IVD: RUO Number of Tests: 96 (40 samples in duplicate) Sample Type: Cell Culture Supernatant Sample Volume: 50 μL Pre-diluted (1:5) Assay Range: 0-112.7 nm

CrossLaps? for Culture (CTX-I) ELISA 品牌Immunoassay Systems | IDS 的詳細(xì)介紹

Code:	AC-07F1
Certification:	Research Use Only
Clinical Area:	Animal Research
Type:	Manual
Format:	ELISA
RUO/IVD:	RUO
Number of Tests:	96 (40 samples in duplicate)
Sample Type:	Cell Culture Supernatant
Sample Volume:	50 μL Pre-diluted (1:5)
Assay Range:	0-112.7 nm

Unique Features

Screening of Anti-Resorptive Drugs1,2,3
High throughput screening of osteoclastic resorptive activity
Multiple testing of single osteoclast cultures over time
Objective assessment of in vitro bone resorption
High correlation to pit area
Dynamic monitoring of bone cultures
Improved lab productivity due to multi-well screening formats
Easy to perform – one step incubation
A complete assay panel supporting bone research

Product Description

The test is an enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of degradation products of C-terminal telopeptides of type I collagen in bone cell culture supernatants.

Type I collagen accounts for more than 90% of the organic matrix of bone. During renewal of the skeleton bone matrix is degraded and consequently fragments of type I collagen are released into circulation.

The resorption process can be studied in vitro by culturing bone cells on devitalised slices of bone or dentin.

The CrossLaps® for Culture (CTX-I) ELISA is based on the observation that certain C-telopeptide degradation products from type I collagen released during osteoclastic bone resorption occur in the circulation as modified di-peptides. These modified (β-isomerised) and cross-linked di-peptides (Glu-Lys-Ala-His-Asp-β-Gly-Gly-Arg) must be covalently cross-linked through the lysine residue for signal in the CrossLaps® for Culture ELISA.

This epitope is present in type I collagen of many species, including human, bovine, elephant and chicken. However, it is not present in rat and mouse.

Publications

Zhuo Y et al., Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible. Bone. 2014 Jul 16;67C:269-280.

Leung P et al., The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone. 2011 Oct;49(4):623-35.

Schaller S et al., In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol. 2005 Oct;3(5):553-80.